Mylan to buy Agila of India for $1.6 billion

  • February 28, 2013

CANONSBURG (AP) — Generic drug maker Mylan Inc. says it will buy Agila Specialties for $1.6 billion in cash, expanding its offerings of injectable drugs and its sales in international markets.

Southpointe-based Mylan is buying Agila from Strides Arcolab. It could pay Strides another $250 million based on other undisclosed conditions. Mylan said the deal will give it new generic injectable drugs and will help it enter the market in emerging markets like Brazil.

Mylan expects the Agila purchase will add to its earnings. The transaction is expected to close in the fourth quarter.

Both Agila and Strides are based in India.

Mylan is one of the biggest generic drug companies in the world. Its sales grew 11 percent to $6.8 billion in 2012.


blog comments powered by Disqus

Mylan announces plans for low-cost AIDS treatment

Construction spending rises to highest level in 8 years

Factory activity drops in Nov.; first decline in 3 years

GM, Fiat Chrysler sales up in November, but Ford was flat

Cyber Monday sales still on top, but losing some luster

Fed moves to bar bailouts of failing firms

Pending homes sales edge up in October

PA Mug Co. owner moves to new studio space in Waynesburg

On the money: Making sure green home upgrades pay off

Dakota city that grew on fracking reaching out for more retail